In a comparison of injectable GLP-1 receptor agonists, semaglutide (Wegovy) appeared to edge out liraglutide (Saxenda) when it came to weight loss, according to the phase IIIb STEP 8 study. In a ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

The obesity medication liraglutide is safe and effective in children aged 6 to <12 years, new research being presented at the annual meeting of the European Association for the Study of Diabetes (EASD ...

GLP-1 drugs have transformed the conversation around obesity and diabetes. Medicines such as semaglutide and liraglutide are ...

Thank you for submitting your question. Keep reading Forbes Advisor for the chance to see the answer to your question in one of our upcoming stories. Our editors also may be in touch with follow-up ...

New study reveals semaglutide outperforms liraglutide in weight loss for obesity, highlighting key factors that contribute to significant weight reduction in patients. Study: One-Year Weight Reduction ...

The FDA's approval of the glucagon-like peptide receptor agonist marks the first non-insulin drug approved for youth with type 2 diabetes since the approval of metformin for pediatric use in 2000.

In recent years, diabetes advocacy groups have called for greater attention to measures beyond glycated hemoglobin when evaluating diabetes drugs, because avoiding hypoglycemia and spending more time ...

Talk about a leg up. Researchers say that taking a popular obesity medication and exercising regularly can lead to weight loss — and bone health is still maintained. Bone loss typically accompanies ...

SAN FRANCISCO —The glucagon-like peptide-1 (GLP-1) agonist liraglutide (Victoza, Novo Nordisk) taken every day preserved postprandial insulin secretion for 1 year after type 1 diabetes diagnosis in ...

Share on Pinterest Can a GLP-1 drug help protect against cognitive decline? Early trials say ‘yes.’ Image credit: Halfpoint Images/Getty Images. Over the last year, the use of and interest in glucagon ...

Treatment with liraglutide (3.0 mg once daily for 3 years), a glucagon-like peptide 1 receptor agonist that lowers levels of glucose and reduces body weight, reduced the risk of 'on treatment' type 2 ...